AstraZeneca Lynparza supplemental application gets US priority review
AstraZeneca
10,292.00p
16:49 14/11/24
1.46%
148.00p
AstraZeneca said that its Lynparza breast cancer drug's supplemental new application had been accepted and granted Priority Review by the US Food and Drug Administration.
FTSE 100
8,071.19
16:49 14/11/24
n/a
n/a
FTSE 350
4,459.02
16:38 14/11/24
n/a
n/a
FTSE All-Share
4,417.25
16:54 14/11/24
n/a
n/a
Pharmaceuticals & Biotechnology
19,794.96
16:38 14/11/24
0.96%
187.95
Lynparza is used to treat patients with early breast cancer who have already received chemotherapy either before or after surgery, the company said on Tuesday.
The Anglo-Swedish added the application was based on results from the OlympiA phase 3 trial which showed Lynparza demonstrated a statistically significant improvement in invasive disease-free survival.